Digital Look

Welcome to Digital Look++,
you are not logged in

PureTech Health (PRTC)

Pharma and Biotech

138.80p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
30-Jun-24	Interim	0.29	(55.03)	(15.00)¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-19	9.81	478.47	149.00¢	2.8	n/a	n/a	n/a	0.0%
31-Dec-20	11.77	18.97	2.00¢	261.7	n/a	-99%	n/a	0.0%
31-Dec-21	17.39	(58.95)	(21.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	15.62	(92.78)	(18.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	3.33	(36.10)	(24.00)¢	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-24	2.50	(137.05)	(43.27)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-25	6.50	(144.30)	(45.20)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-26	14.00	(147.40)	(49.84)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	2.85	n/a	45.82	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.